Drugs / measles
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | ProQuad | — | 2006-04-05 | europa.eu ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00829010 Background | Feb 2009 → Jun 2011 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-06-06 | GlaxoSmithKline | GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older gsk.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | measles | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00829010 ↗ |
| Modality | Vaccine | “2 doses of measles vaccine” NCT00829010 ↗ |